fluticasone furoate; umeclidinium bromide; vilanterol trifenatate - Profile

What are the generic sources for fluticasone furoate; umeclidinium bromide; vilanterol trifenatate and what is the scope of patent protection?

Fluticasone furoate; umeclidinium bromide; vilanterol trifenatate is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Fluticasone furoate; umeclidinium bromide; vilanterol trifenatate has one hundred and ninety-nine patent family members in forty-nine countries.

Summary for fluticasone furoate; umeclidinium bromide; vilanterol trifenatate

International Patents:	199
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for fluticasone furoate; umeclidinium bromide; vilanterol trifenatate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for fluticasone furoate; umeclidinium bromide; vilanterol trifenatate

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRELEGY ELLIPTA	Powder for Inhalation	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	200 mcg/62.5 mcg/ 25 mcg	209482	1	2026-03-19
TRELEGY ELLIPTA	Powder for Inhalation	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	100 mcg/62.5 mcg/ 25 mcg	209482	1	2025-11-26

US Patents and Regulatory Information for fluticasone furoate; umeclidinium bromide; vilanterol trifenatate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes			Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes			Y

Expired US Patents for fluticasone furoate; umeclidinium bromide; vilanterol trifenatate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020

International Patents for fluticasone furoate; umeclidinium bromide; vilanterol trifenatate

Country	Patent Number	Title	Estimated Expiration
Australia	2010326798
Australia	2014204459
Australia	2016262698

Supplementary Protection Certificates for fluticasone furoate; umeclidinium bromide; vilanterol trifenatate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506844	18C1022	France		PRODUCT NAME: COMBINAISON COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (EN PARTICULIER LE BROMURE D'UMECLIDINIUM), DU VILANTEROL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (EN PARTICULIER LE TRIFENATATE DE VILANTEROL), ET DU FUROATE DE FLUTICASONE; REGISTRATION NO/DATE: EU/1/17/1236 20171117
1740177	570	Finland
1740177	300694	Netherlands		PRODUCT NAME: UMECLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140430

Investment Scenario, Market Dynamics, and Financial Trajectory for Fluticasone Furoate; Umeclidinium Bromide; Vilanterol Trifenatate

Last updated: February 3, 2026

Summary

This analysis evaluates the current market landscape, growth prospects, and investment considerations for the combination drug Fluticasone Furoate (FF); Umeclidinium Bromide (UMEC); Vilanterol Trifenatate (VI), primarily marketed as Trelegy Ellipta. The therapy is indicated for COPD and asthma, positioning it within a competitive respiratory pharmacotherapy segment. The assessment covers market size, growth drivers, competitive environment, regulatory landscape, and financial forecasts, emphasizing potential investment risks and opportunities.

---

What is the Current Market Context for Fluticasone Furoate; Umeclidinium Bromide; Vilanterol Trifenatate?

Market Introduction and Product Profile

• Combination Therapy: Triple inhaled therapy combining corticosteroid (FF), long-acting muscarinic antagonist (UMEC), and long-acting beta-agonist (VI).
• Approved Use: Predominantly for COPD; also authorized for asthma in select markets.
• Marketed as: Trelegy Ellipta by GlaxoSmithKline (GSK).

Market Penetration and Sales Overview

• 2019 Launch: GSK launched Trelegy Ellipta in the US, Europe, and other regions, aiming to address the high unmet need for once-daily inhalers.

• Sales Data:	Year	Global Sales (USD millions)	Market Share
  2020	1,200	3.5%
  2021	1,800	4.8%
  2022	2,500	6.2%

(Source: EvaluatePharma, 2022)

Market Drivers

• Increasing prevalence of COPD globally, expected to reach 174 million cases by 2025.
• Growing awareness and diagnosis rates.
• Preference for once-daily inhalers improving adherence.
• Competitive positioning against dual therapies and newer biologics.

---

Market Dynamics and Competitive Landscape

Key Therapeutic Competitors

Competitor Product	Active Ingredients	Market Position	Approximate 2022 Sales (USD millions)
Symbicort (Budesonide/Formoterol)	ICS + LABA	Leading	3,300
Advair (Fluticasone/Salmeterol)	ICS + LABA	Declining	2,600
Breo Ellipta (Fluticasone/Vilanterol)	ICS + LABA	Head-to-head	2,200
Duaklir Genuair (Aclidinium/Formoterol)	LAMA + LABA	Niche	850

Market Share Distribution (2022)	Segment	Market Share
ICS + LABA	30%
Triple Therapy	20%
LAMA + LABA	15%
Others	35%

(Source: IQVIA, 2022)

Pricing and Reimbursement Trends

• Pricing: Premium pricing for combination inhalers; Trelegy Ellipta approximately USD 350 per month in the US.
• Reimbursement: Favorable, driven by clinical efficacy, adherence benefits, and pervasiveness of COPD.

Regulatory Developments

• FDA & EMA Approvals: Approved in 2017 (US) and 2018 (EU).
• Physician Adoption: Steady; high prescribing levels in primary care and pulmonology.
• Pediatric & Alternative Indications: Limited, focusing mainly on COPD and adult asthma.

---

Financial Trajectory and Forecasting

Revenue Projections (2023–2028)

Year	Estimated Global Sales (USD millions)	Assumptions
2023	3,200	Moderate market penetration growth
2024	3,700	Expanded indication and increased awareness
2025	4,200	New formulations, potential biosimilar competition
2026	4,600	Market saturation, price stabilization
2027	4,900	Slight decline in pricing, volume stability
2028	5,200	Maturation of market

Annual Growth Rate (CAGR 2023–2028): Approx. 12-15%

Cost and Margin Dynamics

• R&D: High initial investment, diminishing marginal costs over time.
• Manufacturing: Economies of scale; low variable costs after scale-up.
• Profit Margins: Expected gross margin of 65-70%; net margins around 25-30%.

Investment Outlook

• Expansion Opportunities: Pipeline development for new formulations and indications.
• Market Risks: Patent expirations, biosimilar entry (e.g., for ICS components).
• Pricing Pressures: Healthcare reforms may induce cost containment.

---

Table: Competitive and Investment Considerations

Aspect	Details	Implication
Market Size	2022 global COPD market USD 17 billion	Growing through aging population
Growth Drivers	Increased COPD diagnosis, adherence, once-daily dosing	Positive for Trelegy Ellipta
Barriers	Patent protections (expiring post-2027), biosimilar threats	Cap potential upside
Revenue Potential	$5.2 billion by 2028	High, but dependent on market penetration
R&D Pipeline	Focus on combination therapies, biologics	Innovation-driven growth

---

Comparison With Similar Respiratory Treatments

Feature	Fluticasone / Umeclidinium / Vilanterol	Dual Combinations	Monotherapies
Dosing	Once daily	Once or twice daily	Varies
Indications	COPD, asthma	COPD only	COPD, asthma
Market Penetration	High	Moderate	Varies
Revenue Contribution	Significant	Less	Varies

---

Regulatory & Patent Landscape

Patent Type	Status	Remaining Duration
Composition of Matter	Expired (2017–2020)	Limited
Method of Use	Pending or active	3–8 years
Manufacturing Process	Patented	5–10 years

Note: Patent expirations may lead to biosimilar or generic entry post-2027, impacting revenue streams.

---

FAQs

1. What are the main growth drivers for Trelegy Ellipta?

Increasing COPD prevalence, favorable reimbursement policies, and patient preference for once-daily regimens.

2. How does patent expiration influence long-term revenue forecasts?

Expiration opens pathways for biosimilar competition, potentially eroding market share and profitability after 2027, necessitating innovation and pipeline development.

3. What are the main competitive threats?

Biosimilars, new biologics, and alternative combination therapies could disrupt the current market shares. Price competition could also pressure margins.

4. What regulatory factors could impact future commercialization?

Changes in healthcare policy, stricter pricing controls, or delayed approvals of pipeline drugs could affect financial trajectories.

5. How does market penetration compare across regions?

Higher in North America and Europe due to established healthcare infrastructure; emerging in Asia-Pacific with rapid COPD diagnosis growth.

---

Key Takeaways

• Market Potential: The global COPD therapy market is poised for steady growth, with Trelegy Ellipta representing a significant share within triple inhaler therapies.
• Financial Outlook: Revenue is expected to grow at a CAGR of approximately 12-15% through 2028, reaching around USD 5.2 billion.
• Competitive Risks: Patent expiration post-2027 may lead to biosimilar entry and heighten price competition.
• Investment Opportunities: Innovation in formulations, expansion into new indications, and pipeline development are critical for sustained growth.
• Strategic Focus: Companies should monitor regulatory changes, biosimilar landscape, and payer policies to manage long-term revenue streams.

---

References

[1] EvaluatePharma, 2022
[2] IQVIA, 2022
[3] GSK Annual Report, 2022
[4] Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2022
[5] European Medicines Agency, 2022